PURPOSE: The objective of this study was to investigate the effect of new 4-maleamic acid and 4-maleamide peptidyl chalcone derivatives against human prostate cancer in vitro and in vivo. METHODS: From a series of 21 chalcones, the effects of the three best inhibitors of PC-3 and LNCaP cell viability on growth, including cell cycle changes, adhesion, migration, and cell invasion, as well as their ability to inhibit angiogenesis, clonogenic activity, and matrix metalloproteinases MMP-2 and MMP-9, were tested. The effects in vivo were studied in PC-3 and LNCaP xenografts. RESULTS: Three of the examined chalcones reduced cell viability in both cell lines in a strong dose- and time-dependent manner. An inhibition of the cell cycle progress was observed. These changes were accompanied with the inhibition of cell adhesion, migration, and invasion as well as with reduced neovascularization in chick embryos, tumor colony formation, and MMP-9 activity. The in vivo results demonstrated the strong activity of these structures as inhibitors of tumor development in nude mice compared to non-treated animals. CONCLUSION: The results suggest the multitarget efficacy of 4-maleamic acid and 4-maleamide peptidyl chalcones against human prostate cancer cells and emphasize the potential therapeutic relevance of these compounds.
PURPOSE: The objective of this study was to investigate the effect of new 4-maleamic acid and 4-maleamide peptidyl chalcone derivatives against humanprostate cancer in vitro and in vivo. METHODS: From a series of 21 chalcones, the effects of the three best inhibitors of PC-3 and LNCaP cell viability on growth, including cell cycle changes, adhesion, migration, and cell invasion, as well as their ability to inhibit angiogenesis, clonogenic activity, and matrix metalloproteinases MMP-2 and MMP-9, were tested. The effects in vivo were studied in PC-3 and LNCaP xenografts. RESULTS: Three of the examined chalcones reduced cell viability in both cell lines in a strong dose- and time-dependent manner. An inhibition of the cell cycle progress was observed. These changes were accompanied with the inhibition of cell adhesion, migration, and invasion as well as with reduced neovascularization in chick embryos, tumor colony formation, and MMP-9 activity. The in vivo results demonstrated the strong activity of these structures as inhibitors of tumor development in nude mice compared to non-treated animals. CONCLUSION: The results suggest the multitarget efficacy of 4-maleamic acid and 4-maleamide peptidyl chalcones against humanprostate cancer cells and emphasize the potential therapeutic relevance of these compounds.
Authors: Yeo Myeong Lee; Do Young Lim; Hyun Ju Choi; Jae In Jung; Won-Yoon Chung; Jung Han Yoon Park Journal: J Med Food Date: 2009-02 Impact factor: 2.786
Authors: María José Alcaraz; Ana María Vicente; Amparo Araico; José N Dominguez; María Carmen Terencio; María Luisa Ferrándiz Journal: Br J Pharmacol Date: 2004-07-12 Impact factor: 8.739
Authors: Hari Om Saxena; Uzma Faridi; J K Kumar; Suaib Luqman; M P Darokar; Karuna Shanker; Chandan S Chanotiya; M M Gupta; Arvind S Negi Journal: Steroids Date: 2007-08-06 Impact factor: 2.668
Authors: Juan R Rodrigues; Jaime Charris; Rosa Ferrer; Neira Gamboa; Jorge Angel; Bianca Nitzsche; Michael Hoepfner; Michael Lein; Klaus Jung; Claudia Abramjuk Journal: Invest New Drugs Date: 2011-07-12 Impact factor: 3.850
Authors: Lívia B Salum; Wanessa F Altei; Louise D Chiaradia; Marlon N S Cordeiro; Rafael R Canevarolo; Carolina P S Melo; Evelyn Winter; Bruno Mattei; Hikmat N Daghestani; Maria Cláudia Santos-Silva; Tânia B Creczynski-Pasa; Rosendo A Yunes; José A Yunes; Adriano D Andricopulo; Billy W Day; Ricardo J Nunes; Andreas Vogt Journal: Eur J Med Chem Date: 2013-03-06 Impact factor: 6.514